Abstract Body

Background

Broadly neutralizing antibodies (bnAbs) target conserved regions of HIV Env. In clinical practice, HIV rapidly evolves to escape bnAbs via distinct resistance pathways, as described in recent clinical trials. Here, we delineate virus escape from VRC07-523LS in viremic rhesus macaques (RM) infected with a SHIV encoding a clade C Env. 

Methods

In a study testing the impact of bnAbs with/without anti-NKG2A antibody, RMs were infected with SHIV.CH505.v2 and administered VRC07-523LS (30 mg/kg) at week 6 and 10 post-infection. Plasma virus was subjected to single-genome sequencing (SGS) of gp160 env prior to and 1- and 4-weeks post-bnAb.  Envs representing escape mutations were tested for neutralization sensitivity via TZM-bl assay. 

Results

With bnAb administration at week 6, viral load decreased (median –1.37 log10) by week 7, then rebounded (median +1.38) by week 8.  SGS-derived env sequences (n=163 total, median 11 /RM/timepoint) were generated prior, 1-, and 4-weeks post bnAb administration. Baseline plasma virus showed no evidence of selection. Week 7 Envs demonstrated bnAb-selective pressure, with shared mutations primarily at 3 residues: N279S (2/46), N280D (27/46), and R456S (2/46); 70% of sequences contained at least one of these 3 mutations. By week 10, all Env sequences encoded at least one of the mutations (full penetrance), with N280D as predominant (56/65, 86%) and N279S and R456S less frequently (10.8% and 4.6%). In neutralization testing, N280D conferred full resistance to VRC07-523LS, while N279S and R456S conferred partial resistance (1.8-fold and 1.5-fold decrease in IC50, 2% and 9% decrease in maximal inhibition, respectively), but substantial resistance to the related VRC01 (140-fold decrease in IC50 for both). All mutants retained sensitivity to the potent CD4bs bnAbs N6, N49-P9.6, and VRC01.23LS.

Conclusions

In viremic SHIV.CH505.v2-infected RM treated with VRC07-523LS, we found rapid acquisition of several escape mutations that persisted for 4 weeks, despite waning bnAb levels and return to pre-bnAb viral loads, suggesting retention of replication fitness. These mutations are rare in published group M HIV-1 sequences, but identical mutations have been described in the AMP trial (clade C virus) and viremic studies of VRC07-523LS (clade B virus). The consistent elicitation of the same bnAb escape pathways in human and NHP studies confirms NHP model relevance and suggests common VRC01-class bnAb escape pathways across global virus clades and bnAb administration.